132 related articles for article (PubMed ID: 15231676)
1. Prolonged extracellular signal-regulated kinase 1/2 activation during fibroblast growth factor 1- or heregulin beta1-induced antiestrogen-resistant growth of breast cancer cells is resistant to mitogen-activated protein/extracellular regulated kinase kinase inhibitors.
Thottassery JV; Sun Y; Westbrook L; Rentz SS; Manuvakhova M; Qu Z; Samuel S; Upshaw R; Cunningham A; Kern FG
Cancer Res; 2004 Jul; 64(13):4637-47. PubMed ID: 15231676
[TBL] [Abstract][Full Text] [Related]
2. Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.
Hutcheson IR; Knowlden JM; Hiscox SE; Barrow D; Gee JM; Robertson JF; Ellis IO; Nicholson RI
Breast Cancer Res; 2007; 9(4):R50. PubMed ID: 17686159
[TBL] [Abstract][Full Text] [Related]
3. Novel combination of cyclooxygenase-2 and MEK inhibitors in human hepatocellular carcinoma provides a synergistic increase in apoptosis.
Schmidt CM; Wang Y; Wiesenauer C
J Gastrointest Surg; 2003 Dec; 7(8):1024-33. PubMed ID: 14675712
[TBL] [Abstract][Full Text] [Related]
4. Leukotriene D(4) activates MAPK through a Ras-independent but PKCepsilon-dependent pathway in intestinal epithelial cells.
Paruchuri S; Hallberg B; Juhas M; Larsson C; Sjölander A
J Cell Sci; 2002 May; 115(Pt 9):1883-93. PubMed ID: 11956320
[TBL] [Abstract][Full Text] [Related]
5. Adenovirus type 7 induces interleukin-8 production via activation of extracellular regulated kinase 1/2.
Alcorn MJ; Booth JL; Coggeshall KM; Metcalf JP
J Virol; 2001 Jul; 75(14):6450-9. PubMed ID: 11413312
[TBL] [Abstract][Full Text] [Related]
6. Selective potentiation of paclitaxel (taxol)-induced cell death by mitogen-activated protein kinase kinase inhibition in human cancer cell lines.
McDaid HM; Horwitz SB
Mol Pharmacol; 2001 Aug; 60(2):290-301. PubMed ID: 11455016
[TBL] [Abstract][Full Text] [Related]
7. Noncatalytic function of ERK1/2 can promote Raf/MEK/ERK-mediated growth arrest signaling.
Hong SK; Yoon S; Moelling C; Arthan D; Park JI
J Biol Chem; 2009 Nov; 284(48):33006-18. PubMed ID: 19805545
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the MEK1/ERK pathway reduces arachidonic acid release independently of cPLA2 phosphorylation and translocation.
Evans JH; Fergus DJ; Leslie CC
BMC Biochem; 2002 Oct; 3():30. PubMed ID: 12370087
[TBL] [Abstract][Full Text] [Related]
9. Association of mitogen-activated protein kinase pathways with gingival epithelial cell responses to Porphyromonas gingivalis infection.
Watanabe K; Yilmaz O; Nakhjiri SF; Belton CM; Lamont RJ
Infect Immun; 2001 Nov; 69(11):6731-7. PubMed ID: 11598045
[TBL] [Abstract][Full Text] [Related]
10. Nerve growth factor activates brain-derived neurotrophic factor promoter IV via extracellular signal-regulated protein kinase 1/2 in PC12 cells.
Park SY; Lee JY; Choi JY; Park MJ; Kim DS
Mol Cells; 2006 Apr; 21(2):237-43. PubMed ID: 16682819
[TBL] [Abstract][Full Text] [Related]
11. Active ERK1/2 protein interacts with the phosphorylated nuclear constitutive active/androstane receptor (CAR; NR1I3), repressing dephosphorylation and sequestering CAR in the cytoplasm.
Osabe M; Negishi M
J Biol Chem; 2011 Oct; 286(41):35763-35769. PubMed ID: 21873423
[TBL] [Abstract][Full Text] [Related]
12. Calcium-activated RAF/MEK/ERK signaling pathway mediates p53-dependent apoptosis and is abrogated by alpha B-crystallin through inhibition of RAS activation.
Li DW; Liu JP; Mao YW; Xiang H; Wang J; Ma WY; Dong Z; Pike HM; Brown RE; Reed JC
Mol Biol Cell; 2005 Sep; 16(9):4437-53. PubMed ID: 16000378
[TBL] [Abstract][Full Text] [Related]
13. Tectoridin, a poor ligand of estrogen receptor alpha, exerts its estrogenic effects via an ERK-dependent pathway.
Kang K; Lee SB; Jung SH; Cha KH; Park WD; Sohn YC; Nho CW
Mol Cells; 2009 Mar; 27(3):351-7. PubMed ID: 19326083
[TBL] [Abstract][Full Text] [Related]
14. Membrane estrogen receptor-alpha levels predict estrogen-induced ERK1/2 activation in MCF-7 cells.
Zivadinovic D; Watson CS
Breast Cancer Res; 2005; 7(1):R130-44. PubMed ID: 15642162
[TBL] [Abstract][Full Text] [Related]
15. Rapid activation of ERK1/2 and AKT in human breast cancer cells by cadmium.
Liu Z; Yu X; Shaikh ZA
Toxicol Appl Pharmacol; 2008 May; 228(3):286-94. PubMed ID: 18275979
[TBL] [Abstract][Full Text] [Related]
16. Immunoregulatory protein B7-H3 regulates cancer stem cell enrichment and drug resistance through MVP-mediated MEK activation.
Liu Z; Zhang W; Phillips JB; Arora R; McClellan S; Li J; Kim JH; Sobol RW; Tan M
Oncogene; 2019 Jan; 38(1):88-102. PubMed ID: 30082909
[TBL] [Abstract][Full Text] [Related]
17. Extracellular signal-regulated kinase 2 is necessary for mesoderm differentiation.
Yao Y; Li W; Wu J; Germann UA; Su MS; Kuida K; Boucher DM
Proc Natl Acad Sci U S A; 2003 Oct; 100(22):12759-64. PubMed ID: 14566055
[TBL] [Abstract][Full Text] [Related]
18. Combining RNA interference and kinase inhibitors against cell signalling components involved in cancer.
O'Grady M; Raha D; Hanson BJ; Bunting M; Hanson GT
BMC Cancer; 2005 Oct; 5():125. PubMed ID: 16202132
[TBL] [Abstract][Full Text] [Related]
19. Responsiveness to PI3K and MEK inhibitors in breast cancer. Use of a 3D culture system to study pathways related to hormone independence in mice.
Polo ML; Arnoni MV; Riggio M; Wargon V; Lanari C; Novaro V
PLoS One; 2010 May; 5(5):e10786. PubMed ID: 20520761
[TBL] [Abstract][Full Text] [Related]
20. Regulation of Erk1/2 activation by osteopontin in PC3 human prostate cancer cells.
Robertson BW; Bonsal L; Chellaiah MA
Mol Cancer; 2010 Sep; 9():260. PubMed ID: 20868520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
